Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Tomonori Tayama"'
Autor:
Yi Liu, Capucine Baldini, Jameel Muzaffar, David Hong, Olivier Rixe, Christophe Massard, Timothy Yap, Solmaz Sahebjam, Ursa Brown-Glaberman, Andreea Varga, Sergey Efuni, Barbara Kapelan, Eniola Ogunmefun, Tomonori Tayama, Henry Zhao, Denis Healy, Robert Latek, Daisuke Nakashima, Emrullah Yilmaz
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss Suppl 3 (2020)
Externí odkaz:
https://doaj.org/article/661ac478574745f894f0fe0eb1116527
Autor:
Tomonori Tayama, Masatake Ishiuchi, Kenichiro Sugiyama, Yuichi Oka, Hiroshi Maeda, Yoshinori Nagata, Matthew Hruska, Yoshiyuki Kagawa
Publikováno v:
Clinical Pharmacology in Drug Development.
Autor:
Douglas Marsteller, Krina Mehta, Floyd Fox, Tomonori Tayama, Shoko Koshiba, Yi Liu, Matthew Hruska, Sergey Efuni, Maki Hasegawa, Denis Healy
Publikováno v:
Cancer Research. 81:1368-1368
BACKGROUND: KHK2455 is an oral selective inhibitor of Indoleamine 2,3-dioxygenase 1 (IDO1) and is being developed as an active immunotherapy to treat advanced or metastatic solid tumors. IDO1 is a rate-limiting enzyme that converts tryptophan (TRP) t
Autor:
Agron Collaku, Timothy A. Yap, Emrullah Yilmaz, Tomonori Tayama, Solmaz Sahebjam, Eniola Ogunmefun, Robert Latek, Olivier Rixe, David S. Hong, Sergey Efuni, Yi Liu, Vi Kien Chiu, Dmitri O. Grebennik
Publikováno v:
Journal of Clinical Oncology. 36:3040-3040
3040Background: IDO-1 inhibitors have shown antitumor activity in combination with immunotherapeutic agents in multiple cancers. KHK2455 is a novel and selective oral IDO-1 inhibitor. Unlike other ...
Autor:
Satoshi Mikawa, Keiichi Suzuki, Takashi Awata, Takumi Kachi, Hiroshi Kano, Takeshi Hayashi, Akira Nishida, Hirohide Uenishi, Tomonori Tayama, T. Shibata, Yoshinobu Uemoto, Chihiro Kojima, Koki Maeda
Publikováno v:
Nihon Yoton Gakkaishi. 43:187-194
Autor:
Tadao Akizawa, Tatsuo Yamamoto, Daisuke Nakashima, Kazuki Kawakami, Takayuki Tsuji, Sakuo Hoshi, Tomonori Tayama, Hideji Tanaka, Hirotaka Takama
Publikováno v:
Journal of Bioequivalence & Bioavailability.
Darbepoetin alfa (DA) is a hyperglycosylated analog of recombinant human erythropoietin (rHuEPO) that stim u- lates red blood cell production. The aim of this st udy is to investigate the influence of formula concentration on the absorption of DA aft